Chemed (CHE) Projected to Release Quarterly Earnings on Tuesday

Chemed (NYSE:CHE) is projected to post its Q2 2026 results after the market closes on Tuesday, July 28th. Analysts expect the company to post earnings of $5.60 per share and revenue of $665.0360 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 10:00 AM ET.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. During the same period in the previous year, the business posted $5.63 earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, analysts expect Chemed to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Chemed Stock Up 1.4%

CHE opened at $510.28 on Friday. The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of 27.81, a PEG ratio of 1.88 and a beta of 0.52. The firm has a 50 day moving average price of $458.59 and a 200-day moving average price of $433.65. Chemed has a twelve month low of $365.20 and a twelve month high of $517.74. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s payout ratio is 13.08%.

Insider Buying and Selling

In other news, Director Andrea R. Lindell sold 1,347 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director directly owned 4,578 shares in the company, valued at $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the transaction, the chief executive officer directly owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.33% of the company’s stock.

Institutional Investors Weigh In On Chemed

Institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC purchased a new position in shares of Chemed in the fourth quarter worth $26,000. Global Retirement Partners LLC grew its stake in Chemed by 200.0% during the fourth quarter. Global Retirement Partners LLC now owns 87 shares of the company’s stock valued at $37,000 after acquiring an additional 58 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after acquiring an additional 76 shares during the last quarter. Employees Retirement System of Texas bought a new stake in Chemed in the 3rd quarter valued at $64,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Chemed by 5,333.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 163 shares of the company’s stock worth $73,000 after purchasing an additional 160 shares in the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CHE shares. Bank of America boosted their target price on shares of Chemed from $450.00 to $510.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 17th. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Royal Bank Of Canada raised their target price on Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research report on Monday, April 27th. Finally, Zacks Research upgraded Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $480.25.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.